HERCULES, CA--(Marketwired - February 25, 2016) - Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B) today announced CE IVD marking for its QX200™ Droplet Digital™ PCR (ddPCR™) System, the first ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, and Gencurix, Inc. (KOSDAQ: 229000), a leading Korean developer of ...
Bio-Rad Laboratories BIO recently announced the launch of four new Droplet Digital PCR (ddPCR) platforms. The newly introduced instruments include the company's QX Continuum ddPCR system, along with ...
HERCULES, Calif. -- December 4, 2017 -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announces the launch of the QXDx BCR-ABL %IS Kit, the first CE-IVD digital PCR test that can monitor the ...
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of its ...
HERCULES, Calif., 05/18/2020 – Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its CFX96 Dx Real-Time ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), and Gencurix, Inc. (KOSDAQ: 229000), announced the signing of a strategic agreement establishing Bio-Rad as the exclusive distributor of Gencurix’ ...